Insomnia Drug Development Programs Must Include Driving Studies, FDA Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Agency will require driving simulation studies for all new sleep aids and is asking sponsors of currently approved products to conduct such trials. FDA is directing zolpidem-containing product manufacturers to make labeling changes based, in part, on driving data submitted for Transcept’s Intermezzo.
You may also be interested in...
Drug Effects On Driving Need Tiered Evaluation, FDA Says; Patient Reports Inadequate
Draft guidance describes various analyses and studies that can determine a drug’s effect on driving but doesn’t offer much advice on how to determine when a drug needs to progress to a higher level of scrutiny.
Transcept Gains Long-Delayed Approval Of Intermezzo
Indication for insomnia characterized by middle-of-the-night awakening followed by difficulty returning to sleep is a first.
Transcept's NDA Intermission For Insomnia Drug Intermezzo Set To End In First Quarter
Results from a driving impairment study strengthen the case for approval, the company says.